Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

Cambridge, Mass., USA; and Brisbane, Australia, October 5, 2020 – Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response
  •  Needle-free Vaxxas HD-MAP patch offers potential platform to dramatically improve vaccination in  pandemic response by producing more patient-doses from limited quantities of vaccine, enabling  rapid vaccine distribution without refrigeration, and creating a novel option for self-administration. 
  • Initial BARDA funding focuses on clinical demonstration using pandemic influenza vaccine; Vaxxas  investigating opportunities to improve performance of other pandemic vaccines including against  COVID-19, as well as a broad range of non-pandemic infectious disease vaccines.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a $22 million  United States government award to support the deployment of Vaxxas’ proprietary HD-MAP technology  platform in response to pandemic threats to public health. The award is funded through the Biomedical  Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary  for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, and is  aimed at advancing clinical demonstration of Vaxxas’ proprietary HD-MAP patch for pandemic influenza.  Aligned with this approach, Vaxxas is actively investigating opportunities to improve performance of  other pandemic vaccines including against COVID-19, as well as a broad range of non-pandemic  infectious disease vaccines.

Under the terms of the US$22 million award from BARDA, contract number 75A50120C00180, Vaxxas  will perform a phase 1 clinical study using Vaxxas’ high density micro-array patch (HD-MAP) delivering  pandemic influenza vaccine to more than 400 people using both unadjuvanted and adjuvanted vaccine  formulations. The total cost of this project is estimated to be $24.1 million (A$33.4 million) of which 8.5  percent or US$2.1 million (A$2.8 million) will be contributed by Vaxxas. Pandemic influenza vaccine was  selected for this clinical validation study to comprehensively baseline the immune responses and safety  of the novel HD-MAP vaccination platform when used for pandemic preparedness and response. Vaxxas’ HD-MAP platform is attractive for pandemic response as it has clinically shown the potential to  transform vaccine delivery with lower dose requirements, enabling more patient-doses to be  manufactured more quickly from limited vaccine supply. In addition, the Vaxxas HD-MAP patch enables  faster immune onset kinetics and higher antibody responses, potentially resulting in more rapid and  durable disease protection; and vaccines that do not need refrigeration, enabling rapid distribution  using population-scale logistics such as USPS, UPS, FedEx and more. Unlike needle/syringe, the HD-MAP  patch is easy to apply, with studies currently underway to demonstrate self-administration.

In response to demands from collaborators such as Merck, The World Health Organization and the Bill  and Melinda Gates Foundation, Vaxxas has prototyped a compact manufacturing system designed to be  capable of delivering more than 250 million vaccine doses per year.

“We are excited to partner with BARDA to rapidly deploy Vaxxas’ HD-MAP technology, which holds the  promise of significantly improving pandemic response with needle-free vaccine delivery that is more  effective and readily accepted,” Vaxxas Chief Executive Officer David L. Hoey stated. “Having validated  our HD-MAP technology in clinical studies at commercial scale, we stand ready to be among the leading

innovators who can solve critical challenges to global pandemic health crises, going beyond and  enhancing the capabilities enabled by promising vaccines.”

Vaxxas has published comprehensive data from its clinical programs, including the largest microarray  patch clinical vaccination study ever performed which was published in PLoS. In this first clinical  microarray patch study to show dose sparing against standard intramuscular injection with comparable  immune responses at a 1/6 dose, Vaxxas’ HD-MAP immune response was shown to be significantly  higher and have faster onset than by intramuscular injection at comparable doses. Vaxxas HD-MAP is a  9x9mm array of thousands of very short (~250µm) projections, invisible to the naked eye, coated with  vaccine. Application of the HD-MAP to the skin delivers vaccine to abundant populations of immune  cells. Vaccine on HD-MAP has been shown to be stable for 12 months at temperatures as high as 40oC.

More than 750 million vaccinations are given routinely worldwide each year. In the case of pandemic  response, billions of vaccinations may need to occur in a variety of settings. Vaxxas’ HD-MAP has the  potential to create new needle-free vaccine products with enhanced immune response that would be  designed for improved safety, storage, and distribution logistics to extend the reach of vaccines and  improve vaccination efficiency and effectiveness.

About Vaxxas  

Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and  next-generation vaccines with its proprietary HD-MAP technology platform, which uses an ultra-high  density array of projections – invisible to the naked human eye – applied to the skin to rapidly deliver vaccine to the abundant immune cells immediately below the skin surface. This approach can enhance  efficiency and effectiveness of immune response. Vaxxas uses proprietary dry-coating technology that  can eliminate or significantly reduce the need for vaccine refrigeration during storage and  transportation – easing the resource and logistics burden of maintaining the “cold chain.” Leveraging the  potent immunogenic response and thermostability of HD-MAP, Vaxxas is targeting initial applications in infectious disease and oncology.

Vaxxas core technology was developed at the University of Queensland. The company was founded  with the completion of an initial equity financing led by OneVentures Innovation Fund I with co investors Brandon Capital, the Medical Research Commercialisation Fund (MRCF), and US-based  HealthCare Ventures, followed by a further financing led by OneVentures. OneVentures Innovation Fund  I and the MRCF are supported by the Australian Government’s Innovation Investment Fund (IIF)  program. The IIF is an Australian Government venture capital initiative that provides investment capital  and managerial expertise through licensed venture capital fund managers to investee companies. Learn  more at and



For further information, please contact:

Michaella Porter 

WE Communications

Ph: +61 488 217 191


Amy Miller 

WE Communications

Ph: +61 431 072 422